Miraculins Announces Issuance of Independent Analyst's Research Report from New York Based RB Milestone Group

Miraculins Announces Issuance of Independent Analyst's Research Report from New 
York Based RB Milestone Group 
WINNIPEG, MANITOBA -- (Marketwired) -- 08/22/13 -- Miraculins Inc.
(TSX VENTURE:MOM), ("Miraculins" or the "Company") a medical
diagnostic company focused on acquiring, developing and
commercializing diagnostic and risk assessment technologies for unmet
clinical needs, announces today that an independent analyst's
research report has been issued by New York based RB Milestone Group,
LLC ("RB Milestone").  
This Research Report may be obtained directly from RB Milestone
through joining their financial social network, HiAlpha(R), via the
following link www.hialpha-rbmg.com/register or by visiting the
Company's website at http://www.miraculins.com/pdf/independent.pdf.  
The report was independently prepared and funded by RB Milestone;
however, other RB Milestone services have been commissioned by the
About Miraculins Inc. 
Miraculins is a medical diagnostic company focused on acquiring,
developing and commercializing non-invasive technologies for unmet
clinical needs. A significant number of promising diagnostic
opportunities remain un-commercialized because of the sizable gap
between the discovery stage, when research institutions are typically
involved, and the commercialization stage, when the larger commercial
enterprises become interested. Miraculins has direct experience in
bridging this gap. The Company's PreVu(R) technology is a
revolutionary new coronary artery disease risk assessment technology
that measures cholesterol levels in a patient's skin non-invasively,
painlessly and without the need for fasting. The Company's SCOUT
DS(R) system, is the first non-invasive diabetes screening system
designed to provide a highly sensitive and convenient method for
screening for pre-diabetes and type 2 diabetes based on the presence
of diabetes-related biomarkers found in skin. Unlike current
screening methods, a SCOUT DS(R) test requires no blood draw, no
fasting, and no waiting for a lab result. The product has been used
and validated in thousands of patients around the world. The
Company's preeclampsia program is partnered with Alere Inc., one of
the world's largest diagnostic companies. For more information visit
About RB Milestone Group  
RB Milestone Group, LLC is a New York-based equity research and
market intelligence firm offering financial research and
communications expertise. It is dedicated to providing its investment
and media communities with a detailed look into the global mining,
oil & gas, energy, healthcare and technology industries. In addition,
RB Milestone Group offers multi-faceted communication strategies that
provide its investment and media outlets with the pivotal insights,
access and connectivity needed to excel in today's fast paced capital
markets. www.rbmilestone.com.  
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.  
Caution Regarding Forward-Looking Information 
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable Canadian
provincial securities legislation (collectively, "forward-looking
statements"). These forward-looking statements relate to, among other
things, our objectives, goals, targets, strategies, intentions,
plans, beliefs, estimates and outlook, including, without limitation,
our anticipated future operating results, and can, in some cases, be
identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar
expressions. In addition, any statements that refer to expectations,
projections or other characterizations of future events or
circumstances are forward-looking statements.  
These statements reflect management's current beliefs and are based
on information currently available to management. Certain material
factors or assumptions are applied in making forward-looking
statements, and actual results may differ materially from those
expressed or implied in such statements. Important factors that could
cause actual results to differ materially from these expectations
include, among other things: Miraculins' early stage of development,
lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development,
rapid technological change, uncertainties related to forecasts,
competition, potential product liability, additional financing
requirements and access to capital, unproven markets, supply of raw
materials, income tax matters, management of growth, partnerships for
development and commercialization of technology, effects of insurers'
willingness to pay for products, system failures, dependence on key
personnel, foreign currency risk, risks related to regulatory matters
and risks related to intellectual property and other risks detailed
from time to time in Miraculins' filings with Canadian securities
regulatory authorities, as well as Miraculins' ability to anticipate
and manage the risks associated with the foregoing. Additional
information about these factors and about the material factors or
assumptions underlying such forward-looking statements may be found
in the body of this news release. Miraculins cautions that the
foregoing list of important factors that may affect future results is
not exhaustive. When relying on Miraculins' forward-looking
statements to make decisions with respect to Miraculins investors and
others should carefully consider the foregoing factors and other
uncertainties and potential events.  
These risks and uncertainties should be considered carefully and
prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, Miraculins cannot provide
assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to
update or revise any forward-looking statement.  
PreVu(R) and SCOUT DS(R) are registered trademarks of Miraculins Inc.
All Rights Reserved. 2013.
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-453-1596 (FAX)
Press spacebar to pause and continue. Press esc to stop.